ReShape Lifesciences Inc. SEC Filings

Vyome Holdings, Inc. reports results for the three months ended March 31, 2026, showing a small revenue base and higher investment in R&D. Revenue was $31,591, down from $198,581 a year earlier, entirely from its Indian dermatology products and royalties.

The company recorded a net loss of $985,521, compared with $293,974 in the prior-year quarter, driven mainly by increased research and development expense of $666,405 and selling, general and administrative costs of $477,575. Operating cash outflow was $1,435,964.

Liquidity improved after an at-the-market equity program, which raised $5,288,868 of gross proceeds, lifting cash and cash equivalents to $8,795,783 at March 31, 2026. Common shares outstanding rose to 7,018,528. Vyome remains a clinical-stage company focused on immune-inflammatory and rare disease programs, including lead topical candidate VT-1953.

Vyome Holdings, Inc. is asking stockholders to approve four main items at its 2026 annual meeting on April 24 in New York. Investors will vote to re-elect Venkat Nelabhotla and John Tincoff as Class II directors, approve an advisory “say‑on‑pay” for named executive compensation, and ratify Kreit & Chiu CPA LLP as independent auditor for 2026.

A key proposal would amend the charter to cut authorized common stock from 300,000,000 to 50,000,000 shares. The board says this better matches capital needs, reduces potential dilution concerns and may lower Delaware franchise tax from about $155,000 to about $25,000 for tax years 2026 and 2027. As of March 2, 2026, 7,018,528 common shares were outstanding, with additional shares tied to options, plan reserves and warrants.

The proxy details board structure, committee roles—including a specialized AI Committee—beneficial ownership, and 2025 executive pay, including $478,711 in total compensation for CEO Venkat Nelabhotla. The board unanimously recommends voting FOR all proposals.

Vyome Holdings, Inc. is asking stockholders to approve four main items at its 2026 annual meeting on April 24 in New York. Investors will vote to re-elect Venkat Nelabhotla and John Tincoff as Class II directors, approve an advisory “say‑on‑pay” for named executive compensation, and ratify Kreit & Chiu CPA LLP as independent auditor for 2026.

A key proposal would amend the charter to cut authorized common stock from 300,000,000 to 50,000,000 shares. The board says this better matches capital needs, reduces potential dilution concerns and may lower Delaware franchise tax from about $155,000 to about $25,000 for tax years 2026 and 2027. As of March 2, 2026, 7,018,528 common shares were outstanding, with additional shares tied to options, plan reserves and warrants.

The proxy details board structure, committee roles—including a specialized AI Committee—beneficial ownership, and 2025 executive pay, including $478,711 in total compensation for CEO Venkat Nelabhotla. The board unanimously recommends voting FOR all proposals.

Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.

As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.

The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.

Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.

As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.

The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.

Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.

Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.

Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.

The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.

Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.

John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.

Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.

No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.

Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.

No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.

Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.

No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.

Robert Dickey IV, Chief Financial Officer and Director of Vyome Holdings, Inc., reported a change in beneficial ownership related to a merger involving Vyome Therapeutics. The reporting person received 762 shares of Vyome Holdings common stock on 08/15/2025 in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement, which converted every 5,000 Vyome Therapeutics shares into one share of the issuer. The Merger resulted in Vyome Therapeutics becoming a subsidiary of the issuer and the renamed parent company Vyome Holdings, Inc. The Form 4 discloses the acquisition as a non-derivative transaction and indicates the reporting person holds the shares directly.

Venkateswarlu Nelabhotla filed an SEC Form 3 reporting his initial statement of beneficial ownership with respect to Vyome Holdings, Inc. (ticker HIND). The filing, tied to an event dated 08/15/2025, identifies him as both President & CEO and a director. The Form 3 states no securities are beneficially owned by the reporting person. The form is signed and dated 09/11/2025.